In January 2017, Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA) announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, would merge with its organization and become a wholly-owned subsidiary. By joining forces, the effort will be to have Sarah Cannon and Genospace together harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials. Describing themselves as Digital Architects of Genomic Medicine. GenoSpace has been a precision medicine software company developing a comprehensive suite of offerings for securely storing genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical and GenoSpace for Labs facilitate clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research provides dynamic analysis, visualization and collaboration tools on an advanced population analytics platform. GenoSpace for Patient Communities enables patient-centric exploration and advancement of personalized medicine.
